0
New Institutional shareholder
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces today that Gainbridge Novus Nordic has acquired 80,000 shares from Jürgen Kupper, Managing Director at 2cureX GmbH.
Gainbridge Novus Nordic, a Swedish fund managed by Gainbridge Capital, has acquired 80,000 shares from Jürgen Kupper, Managing Director at 2cureX GmbH.
The transaction has taken place as a block trade with no impact on the share price in the market. Jürgen Kupper had previously acquired 169,600 shares through a warrant program. The proceeds from the transaction will cover costs associated with his initial investment as well as taxes related to the warrants. After the transaction Jürgen Kupper will still hold a significant position in 2cureX.
Becoming part of the forward journey
Cedric Jirsell, Portfolio Manager for Gainbridge Novus Nordic comments: "we find 2cureX a very interesting company at an interesting stage following its first commercial order last month. During 2021 they laid the foundation for an accelerated growth during 2022 and 2023 as already established partners across Europe start delivering orders. We are excited about this opportunity to get on board as an investor and become part of the forward journey."
A recognized and respected investor
Fernando Andreu, CEO of 2cureX comments: "we are delighted to welcome Gainbridge Novus Nordic on board. It's a recognized and respected mid-term investor with a focus on innovation and growth and we see their interest in 2cureX as a recognition of the potential of the company. We are looking forward to further strengthening our investor base by attracting more Nordic and international institutional investors like them."
For more information about 2cureX:
Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com
About 2cureX
2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.
The first two IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.
According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se
About Gainbridge Novus Nordic
Gainbridge Novus Nordic is a special fund pursuant to the Swedish Act (2013:561) on Managers of Alternative Investment Funds.
The fund is managed by Gainbridge Capital AB as an actively managed fund that makes investments in equities and equity-related transferable securities with a focus on innovative and entrepreneurial growth companies.
The focus of the fund is investments in companies that are listed or are about to be listed on a MTF market. Investments are made primarily in companies that carry out some form of capital raising but also directly in secondary markets. Investments are usually held over the medium to long term while the company takes its next steps in its growth journey.
This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-01-21 12:30 CET.
2cureX har en betalt digital IR-aftale med ProInvestor.com
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces today that Gainbridge Novus Nordic has acquired 80,000 shares from Jürgen Kupper, Managing Director at 2cureX GmbH.
Gainbridge Novus Nordic, a Swedish fund managed by Gainbridge Capital, has acquired 80,000 shares from Jürgen Kupper, Managing Director at 2cureX GmbH.
The transaction has taken place as a block trade with no impact on the share price in the market. Jürgen Kupper had previously acquired 169,600 shares through a warrant program. The proceeds from the transaction will cover costs associated with his initial investment as well as taxes related to the warrants. After the transaction Jürgen Kupper will still hold a significant position in 2cureX.
Becoming part of the forward journey
Cedric Jirsell, Portfolio Manager for Gainbridge Novus Nordic comments: "we find 2cureX a very interesting company at an interesting stage following its first commercial order last month. During 2021 they laid the foundation for an accelerated growth during 2022 and 2023 as already established partners across Europe start delivering orders. We are excited about this opportunity to get on board as an investor and become part of the forward journey."
A recognized and respected investor
Fernando Andreu, CEO of 2cureX comments: "we are delighted to welcome Gainbridge Novus Nordic on board. It's a recognized and respected mid-term investor with a focus on innovation and growth and we see their interest in 2cureX as a recognition of the potential of the company. We are looking forward to further strengthening our investor base by attracting more Nordic and international institutional investors like them."
For more information about 2cureX:
Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com
About 2cureX
2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.
The first two IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.
According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se
About Gainbridge Novus Nordic
Gainbridge Novus Nordic is a special fund pursuant to the Swedish Act (2013:561) on Managers of Alternative Investment Funds.
The fund is managed by Gainbridge Capital AB as an actively managed fund that makes investments in equities and equity-related transferable securities with a focus on innovative and entrepreneurial growth companies.
The focus of the fund is investments in companies that are listed or are about to be listed on a MTF market. Investments are made primarily in companies that carry out some form of capital raising but also directly in secondary markets. Investments are usually held over the medium to long term while the company takes its next steps in its growth journey.
This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-01-21 12:30 CET.
2cureX har en betalt digital IR-aftale med ProInvestor.com
